Company Profile

PLx Pharma Inc (AKA: PLX OPCO Inc)
Profile last edited on: 12/2/2023      CAGE: 42EY9      UEI: UPF8J59ECZL7

Business Identifier: GI-safer formulations of proven NSAIDs
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

8285 El Rio Suite 130
Houston, TX 77054
   (713) 842-1249
Location: Single
Congr. District: 09
County: Harris

Public Profile

PLx Pharma Inc., (NASDAQ:PLXP) is a late-stage specialty pharmaceutical company organized around developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin using the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing anti-platelet effectiveness for cardiovascular disease prevention. The firm's product pipeline also includes other oral NSAIDs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation. In December 2016, publicly traded Dipexium Pharmaceuticals Inc. and closely held PLx Pharma Inc. merged in a stock swap in which PLx shareholders received newly issued Dipexium common shares. PLx had earlier filed for its own IPO on the Nasdaq but later in 2016 withdrew. Effective as of April 2017, the combined company—which changed its name to PLx Pharma Inc. immediately following the merger—began trading on the NASDAQ Capital Market under the symbol “PLXP”

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 2 NIH $2,286,885
Project Title: Aspirin-PC for Chemoprevention of Colorectal Cancer
2013 2 NIH $1,276,332
Project Title: GI-Safer Formulation of Indomethacin for Use in Preterm Neonates
2009 2 NIH $1,009,313
Project Title: Gi-Safer Naproxen Formulation R&D for the Treatment of Osteoarthritis and Related
2008 2 Army $847,384
Project Title: PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs

Key People / Management

  Natasha Giordano -- Chief Executive Officer, President and Director

  Ronald R Zimmerman -- Founder

  David Jorden -- Acting Chief Financial Officer

  Lenard M Lichtenberger -- Founder and Chairman, Scientific Advisory Board

  Jason E Moore -- Vice President

  Gary Mossman -- Chief Operating Officer (COO)

  Michael Valentino -- Executive Chair